Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease
- PMID: 16186542
- DOI: 10.1212/01.wnl.0000176071.08694.cc
Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease
Abstract
Among 27 preclinical carriers of the Huntington disease mutation (PMC), the authors found normal striatal values for MRI volumetry in 88% and for fluorodesoxyglucose PET metabolic index in 67%. Raclopride PET binding potential (RAC-BP) was decreased in 50% and correlated with increases in the product of age and CAG repeat length (p < 0.0005). Dopamine D2 receptor availability measured by RAC-BP seems the most sensitive indicator of early neuronal impairment in PMC.
Similar articles
-
Imaging addiction: D2 receptors and dopamine signaling in the striatum as biomarkers for impulsivity.Neuropharmacology. 2014 Jan;76 Pt B(0 0):498-509. doi: 10.1016/j.neuropharm.2013.06.031. Epub 2013 Jul 10. Neuropharmacology. 2014. PMID: 23851257 Free PMC article. Review.
-
PET studies of D2-receptor binding in striatal and extrastriatal brain regions: Biochemical support in vivo for separate dopaminergic systems in humans.Synapse. 2010 Jun;64(6):478-85. doi: 10.1002/syn.20765. Synapse. 2010. PMID: 20175222
-
Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease.Eur J Neurol. 2009 Feb;16(2):226-31. doi: 10.1111/j.1468-1331.2008.02390.x. Epub 2008 Dec 9. Eur J Neurol. 2009. PMID: 19138335
-
[Huntington disease].Nihon Rinsho. 2002 Apr;60 Suppl 4:417-21. Nihon Rinsho. 2002. PMID: 12013902 Review. Japanese. No abstract available.
-
Huntington's disease progression. PET and clinical observations.Brain. 1999 Dec;122 ( Pt 12):2353-63. doi: 10.1093/brain/122.12.2353. Brain. 1999. PMID: 10581228
Cited by
-
Hybrid 2-[18F] FDG PET/MRI in premanifest Huntington's disease gene-expansion carriers: The significance of partial volume correction.PLoS One. 2021 Jun 11;16(6):e0252683. doi: 10.1371/journal.pone.0252683. eCollection 2021. PLoS One. 2021. PMID: 34115782 Free PMC article.
-
MR Biomarkers of Degenerative Brain Disorders Derived From Diffusion Imaging.J Magn Reson Imaging. 2020 Dec;52(6):1620-1636. doi: 10.1002/jmri.27019. Epub 2019 Dec 13. J Magn Reson Imaging. 2020. PMID: 31837086 Free PMC article. Review.
-
Novel Imaging Biomarkers for Huntington's Disease and Other Hereditary Choreas.Curr Neurol Neurosci Rep. 2018 Oct 5;18(12):85. doi: 10.1007/s11910-018-0890-y. Curr Neurol Neurosci Rep. 2018. PMID: 30291526 Free PMC article. Review.
-
Multiple clinical features of Huntington's disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration.J Neurol. 2019 Mar;266(3):551-564. doi: 10.1007/s00415-018-8940-6. Epub 2018 Jun 28. J Neurol. 2019. PMID: 29956026 Review.
-
Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease.Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1546-1556. doi: 10.1007/s00259-018-4033-0. Epub 2018 May 1. Eur J Nucl Med Mol Imaging. 2018. PMID: 29717332 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous